EUVIMEDEUVIMED entdecken
Open Access

Influenza Vaccine Effectiveness Against Medically Attended Outpatients Illness, United States, 2023–2024 Season

Jessie R Chung iD, Ashley M Price, Richard K Zimmerman iD, Krissy Moehling Geffel iD, Stacey L House, Tara Curley, Karen J Wernli iD, C Hallie Phillips, Emily T Martin, Ivana A Vaughn iD, Vel Murugan iD, Matthew Scotch iD und 11 weitere

Clinical Infectious Diseases · 06.11.2025 · 81 (4) · e184-e191

DOI: 10.1093/cid/ciae658 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 06.01.2025. Verfasst von Jessie R Chung und 22 weiteren Autor:innen. Beteiligte Einrichtung: Influenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Influenza, Human, Influenza Vaccines, Vaccine Efficacy. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCIRD CDC HHS, NCATS NIH HHS, US Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The 2023–2024 US influenza season was characterized by a predominance of A(H1N1)pdm09 virus circulation with cocirculation of A(H3N2) and B/Victoria viruses. We estimated vaccine effectiveness (VE) in the United States against mild-to-moderate medically attended influenza illness in the 2023–2024 season.

Methods

We enrolled outpatients aged ≥8 months with acute respiratory illness in 7 states. Respiratory specimens were tested for influenza type/subtype by reverse-transcriptase polymerase chain reaction. Influenza VE was estimated with a test-negative design comparing odds of testing positive for influenza among vaccinated versus unvaccinated participants. We estimated VE by virus subtype/lineage and A(H1N1)pdm09 genetic subclades.

Results

Among 6629 enrolled patients, 1780 (27%) tested positive for influenza, including 806 with A(H1N1)pdm09, 567 with B/Victoria, and 328 with A(H3N2). VE against any influenza illness was 44% (95% confidence interval, 36%–51%): 29% (15%–41%) against influenza A(H1N1)pdm09, 74% (65%–81%) against B/Victoria, and 30% (8%–47%) against A(H3N2). Statistically significant protection against any influenza was found for all age groups except adults aged 50–64 years. Lack of protection in this age group was specific to influenza A–associated illness. We observed differences in VE by birth cohort and A(H1N1)pdm09 virus genetic subclade.

Conclusions

Vaccination reduced outpatient medically attended influenza overall by 44% and provided protection overall against circulating influenza A and B viruses. Serologic studies would help inform differences observed by age groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanInfluenza VaccinesVaccine EfficacyHumansMaleFemaleMiddle AgedUnited StatesAdultOutpatientsAdolescentInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeYoung AdultAgedChildChild, PreschoolInfluenza B virusSeasonsInfantVaccinationAged, 80 and over

Stichwörter der Autor:innen

case controlinfluenzatest-negative designvaccinationvaccine effectiveness

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • Influenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Department of Family Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Emergency Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri, USA.
  • Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
  • Department of Health System Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.
  • Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.

ORCID-Profile: Jessie R Chung, Richard K Zimmerman, Krissy Moehling Geffel, Karen J Wernli, Ivana A Vaughn, Vel Murugan, Matthew Scotch, Elie A Saade, Kiran A Faryar, Manjusha Gaglani, Marie K Kirby, Lisa M Keong, Sascha R Ellington, Brendan Flannery

Förderung

  • NCIRD CDC HHS
  • NCATS NIH HHS
  • US Centers for Disease Control and Prevention
  • NIH HHS
  • Intramural CDC HHS
  • National Institutes of Health

Zitieren

APA

Chung, J. R., Price, A. M., Zimmerman, R. K., Moehling Geffel, K., House, S. L., Curley, T., Wernli, K. J., Phillips, C. H., Martin, E. T., Vaughn, I. A., Murugan, V., Scotch, M., Saade, E. A., Faryar, K. A., Gaglani, M., Ramm, J. D., Williams, O. L., Walter, E. B., Kirby, M. K., …, & Flannery, B. (2025). Influenza Vaccine Effectiveness Against Medically Attended Outpatients Illness, United States, 2023–2024 Season. Clinical Infectious Diseases, 81(4), e184-e191. https://doi.org/10.1093/cid/ciae658

Vancouver

Chung JR, Price AM, Zimmerman RK, Moehling Geffel K, House SL, Curley T, et al. Influenza Vaccine Effectiveness Against Medically Attended Outpatients Illness, United States, 2023–2024 Season. Clinical Infectious Diseases. 2025;81(4):e184-e191. doi:10.1093/cid/ciae658

BibTeX
@article{Chung2025,
  author = {Chung, Jessie R and Price, Ashley M and Zimmerman, Richard K and Moehling Geffel, Krissy and House, Stacey L and Curley, Tara and Wernli, Karen J and Phillips, C Hallie and Martin, Emily T and Vaughn, Ivana A and Murugan, Vel and Scotch, Matthew and Saade, Elie A and Faryar, Kiran A and Gaglani, Manjusha and Ramm, Jason D and Williams, Olivia L and Walter, Emmanuel B and Kirby, Marie K and Keong, Lisa M and Kondor, Rebecca and Ellington, Sascha R and Flannery, Brendan},
  title = {Influenza Vaccine Effectiveness Against Medically Attended Outpatients Illness, United States, 2023–2024 Season},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {81},
  number = {4},
  pages = {e184--e191},
  doi = {10.1093/cid/ciae658}
}
Kostenlos starten →